Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of hepatocellular carcinoma with marked immune cell infiltration II

ABSTRACT: Tumor microenvironmental characteristics using gene expression profiles in hepatocellular carcinoma with marked immune stroma (HCC-IS) compared to conventional hepatocellular carcinoma (C-HCC).

ORGANISM(S): Homo sapiens

PROVIDER: GSE124752 | GEO | 2019/06/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profile of hepatocellular carcinoma with marked immune cell infiltration I

Project description:Tumor microenvironmental characteristics using gene expression profiles in hepatocellular carcinoma with marked immune stroma (HCC-IS) compared to conventional hepatocellular carcinoma (C-HCC).

2019-06-07 | GSE124751 | GEO

Gene expression profile of hepatocellular carcinoma with marked immune cell infiltration II

Project description:Gene expression profile of hepatocellular carcinoma with marked immune cell infiltration II

| PRJNA513314 | ENA

Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma

Project description:We performed gene expression profiling of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and mixed type of combined HCC and CC (CHC). In comparison of the profiles, a novel class of HCC expressing CC-like traits was identified. Gene expression profiling of 70 hepatocellular carcinoma (HCC), 13 cholangiocarcinoma (CC), and 7 mixed type of combined HCC and CC (CHC) were performed.

2010-06-09 | E-GEOD-15765 | biostudies-arrayexpress

3-D culture cell lines mimic tumor in hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is one of the main subtypes of primary liver cancer, which accounts for 75-85% of all cases [1]. Despite increasing availability of treatments for liver cancer, HCC clinical trials are not promising since most HCC patients are in an advanced stage of HCC at the time of diagnosis. Additionally, highly metastatic and recurrent phenotype aggravate poor prognosis of liver cancer [2]. Therefore, there is an urgent need to explore the underlying molecular mechanism in HCC progression.

2023-09-18 | PXD036831 | JPOST Repository

Hepatocellular Carcinoma (HCC) biomarker discovery cohort for small RNA profiling

Project description:Patients with Hepatocellular Carcinoma (HCC) and without HCC used for small read cluster identification and small RNA profiling.

2022-06-01 | E-MTAB-8528 | biostudies-arrayexpress

Expression profiling of PBMC from patients with hepatocellular carcinoma

Project description:Aberrant gene expression analysis between peripheral blood mononuclear cell (PBMC) samples from healthy individuals and patients with pancreatic carcinoma, gastric carcinoma and hepatocellular carcinoma (HCC) were identified using Affymetrix gene arrays. Peripheral blood mononuclear cell (PBMC) from healthy individuals, patients with pancreatic carcinoma, gastric carcinoma and HCC were isolated and total RNA was extracted for Affymetrix gene microarray analysis.

2013-08-03 | E-GEOD-49515 | biostudies-arrayexpress

A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration

Project description:Our study aimed to develop an IRG-based survival prediction model for hepatocellular carcinoma (HCC) patients. To validate the expression levels of the model signature genes, we then performed gene expression profiling analysis using data obtained from RNA-seq of 65 HCC patients. Finally, we confirmed the 5-IRG signature has good predictive power by RNA-seq data from tumor tissues and paired adjacent normal tissues.

2022-10-18 | GSE214846 | GEO

Proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies

Project description:We analyzed the proteome of tumor and matched non-tumor biopsies from 51 treatment-naive Hepatocellular carcinoma (HCC) patients by DIA (SWATH). Thereby we aim to find subgroups of patients characterized by specific pathway activation. Furthermore, we aim to find novel factors involved in HCC development and novel biomarkers.

2022-03-14 | PXD025705 | Pride

Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma

Project description:Saliva is rich in proteins, DNA, RNA and microorganisms, and can be regarded as a biomarker library. In order to explore a noninvasive and simple means of early screening for liver cancer, proteomics was used to screen salivary markers of hepatitis B associated liver cancer. We used mass spectrometry coupled isobaric tags for relative and absolute quantitation (iTRAQ)-technology to identify differentially expressed proteins (DEPs). Western blot, immunohistochemistry and enzyme linked immunosorbent assay were used to detect marker expression of in tissues and saliva. Statistical analysis was used to analyze the diagnostic efficacy of the markers was analyzed through statistical analyses. By comparing the hepatocellular carcinoma (HCC) group with non-HCC groups, we screened out 152 salivary DEPs. We found orosomucoid 1(ORM1) had significantly higher expression in saliva of HCC patients compared with non-HCC groups (p<0.001) and the expression of ORM1 in liver cancer tissues was significantly higher than that in adjacent normal tissues(p<0.001). The combination of salivary ORM1 and alpha-fetoprotein (AFP) showed reasonable specificities and sensitivities for detecting HCC. In a word, salivary ORM1 as a new biomarker of hepatitis B associated hepatocellular carcinoma, combination of salivary ORM1 and AFP as an improved diagnostic tool for hepatocellular carcinoma.

2022-07-13 | PXD033752 | Pride

LncRNA profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerous liver tissue

Project description:LncRNA profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue, aimed to analyze the lncRNA expression proﬁle of hepatocellular carcinoma (HCC) and identify prognosis-related lncRNAs.

2023-06-25 | GSE72170 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data